Group 1 - A-shares opened higher today, with significant gains in innovative drug and brain-computer interface stocks, including Zhaoyan New Drug and BeiGene, which rose over 10% [1] - The innovative drug ETF Tianhong (517380) tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index surged over 4.8%, outperforming the Hong Kong Stock Connect Innovative Drug Index [1] - The biopharmaceutical ETF (159859) tracking the Guozhen Biopharmaceutical Index increased by over 3%, with a total scale exceeding 3.3 billion yuan and a net inflow of over 600 million yuan since September last year [1] Group 2 - The National Medical Products Administration has organized the formulation of the "Priority Approval High-end Medical Device Catalog (2025 Edition)," including medical electronic accelerators and implantable brain-computer interface medical devices [1] - Elon Musk announced that his brain-computer interface company, Neuralink, will begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] - Analysts indicate that including implantable brain-computer interface medical devices in the priority approval category highlights policy support for related technological developments, with a broad potential market space and accelerated commercialization processes expected [1] Group 3 - McKinsey estimates that the global market size for brain-computer interface medical applications could reach $40 billion by 2030 and $145 billion by 2040, indicating significant application potential in the medical field [2] - Investors interested in the innovative drug sector can consider the innovative drug ETF Tianhong (517380) for easy access, while off-market investors may focus on linked funds [2] - The emphasis is on CXO and innovative drug mainline trends, with a recommendation to focus on the biopharmaceutical ETF (159859) that targets 30 industry leaders for higher sharpness and elasticity [2]

1月5日，A股节后开门红，三大指数高开高走，沪指重回4000点，时隔34个交易日；市场半日成交额 1.64万亿，较上个交易日放量3238亿。截至午间收盘，沪指涨1.07%，深成指涨1.87%，创业板指涨 2.15%，科创50指数大涨超4%。 盘面上，保险板块走强，新华保险、中国太保双双续创历史新高；脑机接口概念股全线爆发并引爆医药 股，创新医疗等超20股涨停；芯片、半导体产业链大涨，设备、材料、晶圆代工、存储芯片等方向均表 现不俗，东微半导等多股涨停或涨超10%；商业航天概念热度不减，中国卫通5天3板，金风科技等多股 涨停；此外，AI应用、油气、锂电、机器人、游戏等板块盘中均有所表现。下跌方面，海南自贸概念 下挫，海南发展跌停；此外，港口航运、影视、旅游、汽车等板块跌幅居前。 展望后市，中信建投认为， 1月"跨年行情"有望继续演绎。行业主要围绕半导体、AI和未来产业热点展 开。 热门板块 1、脑机接口概念爆发 市场分析认为，A股迎来多重利好消息： 1、人民币、港股、中概股等中国资产假期的强劲表现为A股节后走势注入信心。 2、半导体迎多重利好：国家大基金大比例增持中芯国际、中国芯片整合升级、台积电获美政府年度许 ...

Market Overview - The market is experiencing a broad-based rally, with nearly 4,000 stocks in the Shanghai and Shenzhen markets rising, while fewer than 1,400 stocks are declining [2] - The insurance sector is showing strong performance, with significant stock price increases for companies such as New China Life Insurance, Ping An Insurance, and China Life Insurance [2] - Technology themes, particularly in the semiconductor supply chain and brain-computer interfaces, are also performing actively [2] External Influences - The positive performance of the A-share market is supported by favorable trends in overseas markets during the New Year holiday period [2] - On January 2, the Hong Kong stock market opened with gains, with the Hang Seng Index and the Hang Seng Tech Index both rising [2] - Some market opinions suggest that this positive sentiment may help boost the risk appetite of A-share investors [2]

作者 | 一财 阿驴 11:31 A股午盘丨沪指重返4000点 截至午盘，沪指涨1.07%，深成指涨1.87%，创业板指涨2.15%，科创综指涨超3%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | vam | 4011.45 | 42.61 | 1.07% | | 399001 | 深证成指 | | 13777.32 | 252.29 | 1.87% | | 399006 | 创业板指 | | 3272.07 | 68.90 | 2.15% | | 000680 | 科创综指 | Vim | 1689.67 | 52.97 | 3.24% | 盘面上，保险股涨幅居前，脑机接口概念股掀涨停潮，半导体产业链爆发，AI应用、商业航天题材 活跃。海南自贸区、石油板块调整。 | 板块名称 | 涨幅号 | 涨速 | 涨停数 | | --- | --- | --- | --- | | 脑机接口 | +13.06% | +0.19% | 26 | | 高压氧舱 | +7.12% | +0.1 ...

Market Performance - The A-share market experienced a significant increase, with the Shanghai Composite Index recovering above 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87% to 13777.32, while the ChiNext Index increased by 2.15% to 3272.07 [1] - The total trading volume in the Shanghai and Shenzhen markets reached 16357.79 billion, with over 4000 stocks rising [1] Sector Highlights - The insurance sector led the market, with stocks like New China Life Insurance rising over 8%, reaching a historical high [3] - The insurance industry reported a total premium income of 57629 billion for the first 11 months of 2025, a year-on-year increase of 7.6% [3] - The semiconductor sector saw a collective surge, with stocks like Jiangbolong rising over 14% due to a worsening DRAM supply shortage, with contract prices expected to rise by up to 50% in Q1 2026 [3] - The innovative drug sector was active, with stocks like Guanhao Bio hitting the daily limit, supported by the approval of 76 innovative drugs in 2025, a historical high [3] Analyst Insights - CITIC Securities highlighted that balancing external and internal demand will be a major expectation for 2026, suggesting a trend towards taxing external demand and subsidizing internal demand [4] - Huatai Securities noted that overseas Chinese stocks' performance positively impacts investor sentiment, although geopolitical issues may create short-term volatility [4] - CITIC Jiantou indicated that post-holiday, investor risk aversion is easing, leading to a more active search for opportunities, with a high probability of continued upward trends in A-shares [4]

每经AI快讯，1月5日，指数走强，创业板指拉升涨逾2.00%，沪指涨0.90%，深成指涨1.57%。脑机接 口、保险、半导体芯片、贵金属等涨幅居前，沪深京三市上涨个股近4000只。 每经AI快讯，1月5日，指数走强，创业板指拉升涨逾2.00%，沪指涨0.90%，深成指涨1.57%。脑机接 口、保险、半导体芯片、贵金属等涨幅居前，沪深京三市上涨个股近4000只。 ...

Market Overview - The market opened higher on January 5, with the Shanghai Composite Index returning to the 4000-point level for the first time in 34 trading days, and the ChiNext Index rising over 2% [1] - By the midday close, the Shanghai Composite Index increased by 1.07%, the Shenzhen Component Index rose by 1.87%, and the ChiNext Index gained 2.15% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [1] Index Performance - Shanghai Composite Index: 4011.45, up 1.07% [2] - Shenzhen Component Index: 13777.32, up 1.87% [2] - ChiNext Index: 3272.07, up 2.15% [2] - North Star 50 Index: 1459.32, up 1.31% [2] Sector Highlights - Over 4000 stocks in the market experienced gains, with 98 stocks hitting the daily limit [2] - The brain-computer interface sector saw significant activity, with over twenty constituent stocks hitting the daily limit, including Sanbo Brain Science, Meihao Medical, and Innovation Medical [2] - The commercial aerospace sector remained active, with China Satellite Communications achieving three consecutive trading limits in five days [2] - The insurance sector strengthened, with Xinhua Insurance and China Pacific Insurance both reaching historical highs [2] - The semiconductor industry chain showed robust performance, with stocks like Yaxiang Integration and Shenghui Integration hitting the daily limit [2] - Conversely, the Hainan Free Trade Zone concept stocks collectively declined, with Hainan Development hitting the daily limit down [2]

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

2026 年 01 月 05 日 脑机接口产业化提速，机器人场景 创新，氢能向电网"调节者"转变 ——未来产业周报第 4 期（2025/12/28-2026/1/3） 相关研究 《国家创投引导基金启动，全球多 国加速布局竞逐未来产业——未来 产业周报第 3 期（2025/12/21- 2025/12/27）》 2025/12/28 《硅基量子与脑机临床突破，氢基 能源发展可期，关注开源世界模型 ——未来产业周报第 2 期 （2025/12/14-2025/12/20）》 2025/12/21 证券分析师 王雪蓉 A0230523070003 wangxr@swsresearch.com 陆灏川 A0230520080001 luhc@swsresearch.com 刘洋 A0230513050006 liuyang2@swsresearch.com 王璐 A0230516080007 wanglu@swsresearch.com 傅浩玮 A0230522010001 fuhw@swsresearch.com 牟瑾瑾 A0230524100002 mujj@swsresearch.com 王胜 A0230511 ...

2026年A股开盘首日，脑机接口概念表现活跃。截至发稿，倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗20cm 涨停，创新医疗、南京熊猫10CM涨停，博拓生物、狄耐克等涨超10%。 开源证券最新研报表示， 上述行业事件印证了脑机接口技术预计将在2026年迈向商业化，并从医疗刚需向AI应用、机器人等多领域渗透 。 Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑机接口技术具备双重意义。一方面，这标志着脑机接口从临 床验证阶段开始向商业化规模化阶段迈进，推动脑机接口从"医疗试验工具"到"可普及产品"的落地；另一方面，未来随着技术方案成熟度的 进一步提升，也将为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构进一步表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增蓄势期，根据Precedence Research数据， 预计到2034年全球脑机接口市场规模将增长到约124亿美元 ，2025-2034年CAGR为17%。 在近期Neuralink规模化量 产预期和技术突破的催化下， ...